The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis,
Journal of Cystic Fibrosis · 2024-05 · 23 (3) · 443-449
DOI: 10.1016/j.jcf.2024.03.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024-05. Verfasst von Margaret Rosenfeld und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Washington and Seattle Childrens Hospital, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Spirometry. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation.
Abstract (Originalsprache)
RATIONALE: The American Thoracic Society recommended switching to race-neutral spirometry reference equations, as race is a social construct and to avoid normalizing disparities in lung function due to structural racism. Understanding the impact of the race-neutral equations on percent predicted forced expiratory volume in one second (ppFEV1) in people with cystic fibrosis (PwCF) will help prepare patients and providers to interpret pulmonary function test results. OBJECTIVE(S): To quantify the impact of switching from Global Lung Initiative (GLI) 2012 race-specific to GLI 2022 Global race-neutral reference equations on the distribution of ppFEV1 among PwCF of different races. METHODS: Cross-sectional analysis of FEV1 among PwCF ages ≥6 years in the 2021 U.S. Cystic Fibrosis Foundation Patient Registry. We describe the absolute difference in ppFEV1 between the two reference equations by reported race and the effect of age and height on this difference. RESULTS: With the switch to GLI Global, ppFEV1 will increase for White (median increase 4.7, (IQR: 3.1; 6.4)) and Asian (2.6 (IQR: 1.6; 3.7)) individuals and decrease for Black individuals (-7.7, (IQR: -10.9; -5.2)). Other race categories will see minimal changes in median ppFEV1. Individuals with higher baseline ppFEV1 and younger age will see a greater change in ppFEV1 (i.e., a greater improvement among White and Asian individuals and a greater decline among Black individuals). CONCLUSIONS: Switching from GLI 2012 race-specific reference equations to GLI 2022 Global race-neutral equations will result in larger reductions in ppFEV1 among Black individuals with CF than increases among White and Asian people with CF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, University of Washington and Seattle Childrens Hospital, USA.
- Patient Registry Research, Cystic Fibrosis Foundation, Bethesda, MD, USA. Electronic address: ecromwell@cff.org.
- Division of Pulmonary and Sleep Medicine, Children's Hospital of Richmond at Viriginia Commonwealth University, USA.
- Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, USA.
- Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, USA.
- Division of Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, USA.
Förderung
- Cystic Fibrosis Foundation
Zitieren
APA
Rosenfeld, M., Cromwell, E. A., Schechter, M. S., Ren, C., Flume, P. A., Szczesniak, R. D., Morgan, W. J., & Jain, R. (2024). The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis,. Journal of Cystic Fibrosis, 23(3), 443-449. https://doi.org/10.1016/j.jcf.2024.03.013
Vancouver
Rosenfeld M, Cromwell EA, Schechter MS, Ren C, Flume PA, Szczesniak RD, et al. The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis,. Journal of Cystic Fibrosis. 2024;23(3):443-449. doi:10.1016/j.jcf.2024.03.013
BibTeX
@article{Rosenfeld2024,
author = {Rosenfeld, Margaret and Cromwell, Elizabeth A and Schechter, Michael S and Ren, Clement and Flume, Patrick A and Szczesniak, Rhonda D and Morgan, Wayne J and Jain, Raksha},
title = {The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis,},
journal = {Journal of Cystic Fibrosis},
year = {2024},
volume = {23},
number = {3},
pages = {443--449},
doi = {10.1016/j.jcf.2024.03.013}
}
EUVIMED